| scholarly article | Q13442814 |
| P2093 | author name string | Rübsamen-Waigmann H | |
| von Briesen H | |||
| Duncan IB | |||
| Kreuter J | |||
| Bender AR | |||
| P2860 | cites work | Distribution and Elimination of Poly(methyl-2-14C-methacrylate) Nanoparticle Radioactivity after Injection in Rats and Mice | Q66973943 |
| Infection of monocytes/macrophages by HIV in vitro | Q67660231 | ||
| Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? | Q67887560 | ||
| Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome | Q67895213 | ||
| Reversal of HIV-phenotype to fulminant replication on macrophages in perinatal transmission | Q69375705 | ||
| Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyinosine | Q71711688 | ||
| Safety and activity of saquinavir in HIV infection | Q72152643 | ||
| In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages | Q72182519 | ||
| The neuropathogenesis of HIV-1 infection | Q72182527 | ||
| Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) | Q72294469 | ||
| Mechanisms of HIV/SIV mucosal transmission | Q72527610 | ||
| Membrane permeation mechanisms of 2',3'-dideoxynucleosides | Q72908065 | ||
| Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission | Q22241902 | ||
| How does HIV cause AIDS? | Q22242244 | ||
| Pathogenesis of human immunodeficiency virus infection | Q24634681 | ||
| Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
| Molecular targets for AIDS therapy | Q28323494 | ||
| Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase | Q28325776 | ||
| Rational design of peptide-based HIV proteinase inhibitors | Q28330897 | ||
| HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy | Q28339571 | ||
| Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection | Q29547852 | ||
| Viral dynamics in human immunodeficiency virus type 1 infection | Q29547908 | ||
| The role of mononuclear phagocytes in HTLV-III/LAV infection | Q29618676 | ||
| Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate. | Q33847874 | ||
| HIV inhibitors targeted at the reverse transcriptase | Q35311071 | ||
| Insights into HIV chemotherapy | Q35706677 | ||
| Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems | Q35898340 | ||
| Recent advances in the design of HIV proteinase inhibitors | Q36373061 | ||
| Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future | Q36672648 | ||
| Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages | Q38569781 | ||
| Controversies in anti-retroviral therapy of adults | Q39134403 | ||
| Present Status and Future Prospects for HIV Therapies | Q40486948 | ||
| HIV therapy advances. Update on a proteinase inhibitor | Q40582245 | ||
| The Th1-Th2 hypothesis of HIV infection: new insights | Q40587487 | ||
| HIV protease inhibitors: their anti-HIV activity and potential role in treatment | Q40876005 | ||
| HIV protease inhibitors. | Q41000709 | ||
| Human immunodeficiency virus type 1 causes productive infection of macrophages in primary placental cell cultures | Q41476899 | ||
| Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles | Q42279953 | ||
| Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages | Q43664017 | ||
| Markers for HIV-disease progression in untreated patients and patients receiving AZT: Evaluation of viral activity, AZT resistance, serum cholesterol, β2-microglobulin, CD4+ cell counts, and HIV antigen | Q43866891 | ||
| Secretory repertoire of HIV-infected human monocytes/macrophages | Q44706185 | ||
| Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting | Q44881606 | ||
| Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages | Q45777820 | ||
| In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). | Q45836762 | ||
| Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro | Q45847518 | ||
| Influence of HIV-infection on the phagocytic activity of monocytes/macrophages and granulocytes. | Q54643239 | ||
| Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. | Q55243911 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 1467-1471 | |
| P577 | publication date | 1996-06-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro | |
| P478 | volume | 40 |
| Q34138487 | Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice |
| Q34276856 | Biomedical applications of collagen |
| Q39017307 | Biopolymeric nanoparticles |
| Q59237521 | Body distribution of azidothymidine bound to nanoparticles after oral administration |
| Q73154669 | Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules |
| Q33517859 | Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. |
| Q30651263 | Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir |
| Q37774876 | DNA-based applications in nanobiotechnology |
| Q35145361 | Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons |
| Q35847982 | Gold nanoparticles to improve HIV drug delivery |
| Q41123091 | Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease |
| Q42429063 | Interaction of silver nanoparticles with Tacaribe virus |
| Q40232722 | Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. |
| Q33327051 | Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade |
| Q37508725 | Nanocarriers' entry into the cell: relevance to drug delivery |
| Q37131491 | Nanotechnology in the detection and control of microorganisms |
| Q28246583 | Nanotechnology: intelligent design to treat complex disease |
| Q38807176 | Past, Present, and Future Drug Delivery Systems for Antiretrovirals |
| Q98292337 | Pharmaceutical Approaches to HIV Treatment and Prevention |
| Q36668023 | Polymeric nanogel formulations of nucleoside analogs |
| Q30462494 | Pulsed magneto-motive ultrasound imaging to detect intracellular trafficking of magnetic nanoparticles |
| Q39976449 | Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line |
| Q46678355 | Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice |
| Q33933489 | Transport, metabolism and elimination mechanisms of anti-HIV agents |
| Q39068461 | Use of collagen as a biomaterial: An update |
Search more.